The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic lateral sclerosis (ALS).

In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. ##STR00001##

In one aspect, the present disclosure provides analogs of thailanstatin of the formula wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. ##STR00001##

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

##STR00001##

Disclosed herein are compositions and methods relating to treating, preventing, reducing, and/or inhibiting cancers, infectious diseases, and/or neurological disorders.

Tricyclic compounds, and in particular novel dibenzoxazepin derivates are disclosed herein, which were quite surprisingly found as having OMA1 and/or OPA1 modulatory properties. Compounds of present invention may provide useful for the treatment of certain conditions and diseases, which are amenable to OMA1 and/or OPA1-modulatory therapies. Such conditions may include conditions and diseases prevalent in the elderly, including cancer. Pharmaceutical compositions comprising compounds of present invention may be combined with other treatments or further comprise other pharmaceutically active ingredients.

Tricyclic compounds, and in particular novel dibenzoxazepin derivates are disclosed herein, which were quite surprisingly found as having OMA1 and/or OPA1 modulatory properties. Compounds of present invention may provide useful for the treatment of certain conditions and diseases, which are amenable to OMA1 and/or OPA1-modulatory therapies. Such conditions may include conditions and diseases prevalent in the elderly, including cancer. Pharmaceutical compositions comprising compounds of present invention may be combined with other treatments or further comprise other pharmaceutically active ingredients.

The present disclosure provides a low-molecular mass organic gellant and a preparation method and use thereof, belonging to the technical field of gelled fuels. The low-molecular mass organic gellant has a cyclopropane structure. The cyclopropane structure belongs to a high-tension structure, which endows the gellant with excellent gel properties; in addition, the high-tension cyclopropane structure is also capable of greatly improving a combustion performance of the gellant, shortening an ignition delay time of the fuel, and promoting combustion. Moreover, multiple hydroxyl groups contained in the low-molecular mass organic gellant is capable of effectively forming a gel through hydrogen bonding; therefore, the gellant has excellent gel and shear thinning properties for high-energy density fuel and energetic nanofluid fuel, with a critical gellant concentration of not greater than 1% when forming a stable gel.

The present disclosure provides a low-molecular mass organic gellant and a preparation method and use thereof, belonging to the technical field of gelled fuels. The low-molecular mass organic gellant has a cyclopropane structure. The cyclopropane structure belongs to a high-tension structure, which endows the gellant with excellent gel properties; in addition, the high-tension cyclopropane structure is also capable of greatly improving a combustion performance of the gellant, shortening an ignition delay time of the fuel, and promoting combustion. Moreover, multiple hydroxyl groups contained in the low-molecular mass organic gellant is capable of effectively forming a gel through hydrogen bonding; therefore, the gellant has excellent gel and shear thinning properties for high-energy density fuel and energetic nanofluid fuel, with a critical gellant concentration of not greater than 1% when forming a stable gel.